You just read:

Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers

News provided by

Eli Lilly and Company

May 08, 2020, 20:22 ET